Syvento BioTech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SyVento BioTech is a Warsaw-based CDMO (Contract Development and Manufacturing Organization) focused on lipid nanoparticle (LNP) formulation and mRNA synthesis services. Leveraging a highly qualified R&D team, the company provides integrated platform solutions spanning genetic (RNA synthesis), delivery (LNP design), and manufacturing (scale-up to 50L batches and fill-finish) services. Its business model is built on partnering with biopharma companies to support their therapeutic programs, particularly in RNA-based drugs and vaccines, as evidenced by its active participation in major industry conferences and a recent Letter of Intent with Mabion for fill-finish services.

Drug Delivery

Technology Platform

Integrated platform for RNA therapeutics: 1) Genetic Platform for high-quality mRNA synthesis; 2) Delivery Platform for modular Lipid Nanoparticle (LNP) design and formulation; 3) Manufacturing Platform for scale-up (to 50L) and aseptic fill-finish (2000-3000 vials/hour).

Opportunities

The massive growth in RNA therapeutics and vaccines creates sustained demand for specialized LNP expertise and manufacturing capacity, which is currently constrained.

SyVento's integrated platform, from mRNA synthesis to fill-finish, offers a unique one-stop-shop value proposition for biotechs, especially in Europe.

Partnerships with larger pharma companies seeking to outsource or de-risk their RNA delivery challenges represent a significant growth vector.

Risk Factors

The company faces intense competition from larger, global CDMOs and other niche players scaling up LNP capabilities.

Its financial stability is reliant on securing a steady stream of partner projects, creating client concentration risk.

Successfully scaling processes from development to robust, GMP-compliant commercial manufacturing presents significant technical and operational execution risks.

Competitive Landscape

SyVento competes in the specialized CDMO space for lipid nanoparticles and mRNA services. Key competitors include large, established CDMOs (e.g., Lonza, Catalent, Thermo Fisher/Patheon) with expanding nucleic acid capabilities, and other focused players like eTheRNA, Ethris, or Arcturus's manufacturing arm. SyVento differentiates through its deep scientific focus, integrated platform, and European location, aiming to serve as a agile, expert partner for biotechs.

More companies in Drug Delivery & Formulation →More companies in Poland →